Drug improves survival of patients with rare cancer by almost a quarter
(Cancer Research UK) Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2017 Category: Cancer & Oncology Source Type: news
Oral chemotherapy extends survival by more than a year in biliary tract cancer
(American Society of Clinical Oncology) A phase III randomized clinical trial of 447 patients with biliary tract cancers (BTCs, cancers of the bile duct and gallbladder) showed that giving capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 17, 2017 Category: Cancer & Oncology Source Type: news
ASCO Updates Pancreatic Cancer Guideline to Include Doublet Chemotherapy
ASCO updated a 2016 guideline regarding resected pancreatic cancer to include treatment with adjuvant chemotherapy with gemcitabine and capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - April 24, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gastrointestinal Cancer News Pancreatic Cancer Source Type: news
ASCO Updates Recs on Potentially Curable Pancreatic Cancer
Regimen of gemcitabine, capecitabine preferred in absence of concerns for toxicity, tolerance (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 18, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Pharmacy, Radiology, Surgery, Journal, Source Type: news
Adding Utidelone Improved Outcomes in Heavily Pretreated Breast Cancer
Combining a genetically engineered epothilone analog known as utidelone with capecitabine significantly improved progression-free survival in women with metastatic breast cancer who were refractory to anthracycline and taxane regimens. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news
New drug treatment for pancreatic cancer 'extends survival'
Conclusion
Pancreatic cancer is one of the toughest cancers to treat, with lower survival rates than many other cancers.
Surgery is usually the first treatment, where possible. Some people also have chemotherapy or radiotherapy.
Recent studies have looked into how different types of chemotherapy might help improve survival.
This study shows that a combination of two chemotherapy drugs may help people live longer than taking one drug alone after surgery.
But this doesn't mean everyone taking those drugs will survive at least five years, despite the media headlines.
The researchers estimate 28.8%, or just over a quarter...
Source: NHS News Feed - January 25, 2017 Category: Consumer Health News Tags: Cancer Source Type: news
New drugs hope for pancreatic cancer sufferers
Pairing the chemotherapy drugs gemcitabine and capecitabine dramatically increases the chances of people with pancreatic cancer living at least five years, trial results have shown. (Source: the Mail online | Health)
Source: the Mail online | Health - January 25, 2017 Category: Consumer Health News Source Type: news
Study establishes new standard of care for pancreatic cancer patients
(Cancer Research UK) A combination of two chemotherapy drugs -- gemcitabine and capecitabine -- should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 24, 2017 Category: Cancer & Oncology Source Type: news
Capecitabine (Xeloda) Tablets (Capecitabine Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 17, 2017 Category: Drugs & Pharmacology Source Type: news
Avoiding over-the-counter heartburn medications could save cancer patients' lives
Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse. A new study has discovered that proton pump inhibitors, which are very common medications for heartburn and gastrointestinal bleeding, decrease effects of capecitabine, a type of chemotherapy usually prescribed to gastric cancer patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 16, 2016 Category: Science Source Type: news
Avoiding over-the-counter heartburn meds could save cancer patients' lives
(University of Alberta Faculty of Medicine& Dentistry) Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse. A University of Alberta study published in the journal JAMA Oncology discovered that proton pump inhibitors, which are very common medications for heartburn and gastrointestinal bleeding, decrease effects of capecitabine, a type of chemotherapy usually prescribed to gastric cancer patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 15, 2016 Category: Global & Universal Source Type: news
Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer
A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Henning Schade, MD Lindsey Davis, MD Peter Kabos, MD Tags: Case Studies Colorectal Cancer Oncology Journal Source Type: news
Xeloda (Capecitabine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 19, 2016 Category: Drugs & Pharmacology Source Type: news
Fingerprints Disappear During Capecitabine Therapy Fingerprints Disappear During Capecitabine Therapy
The commonly used chemotherapy agent capecitabine can leave many patients without fingerprints, but the effect is temporary.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 29, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Anti-Cancer Agent "Xeloda®", Obtained Approval for Additional Indication of "Adjuvant Chemotherapy for Rectal Cancer"
(Source: Roche Investor Update)
Source: Roche Investor Update - August 26, 2016 Category: Pharmaceuticals Source Type: news
